Grégory Michel

Grégory Michel

Auto-generated profile, based on publicly available information

Grégory Michel

Affiliations: Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Team “Microbial toxins in host pathogen interactions”, Equipe labellisée ligue contre le cancer, Nice, France, Université de Nice-Sophia Antipolis, Faculté de Médecine, Nice, France, Centre Hospitalier Universitaire de Nice, Laboratoire de Parasitologie-Mycologie, Nice, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Acta Tropica
Verified
Journal Article
Closed access
GMGrégory Michel
Grégory Michel
CPChristelle Pomares
Christelle Pomares
BFBernard Ferrua
Bernard Ferrua
PMPierre Marty
Pierre Marty

13 September 2011 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
GMGrégory Michel
Grégory Michel
BFBernard Ferrua
Bernard Ferrua
TLThierry Lang
Thierry Lang
MMMadhavi P. Maddugoda
Madhavi P. Maddugoda
PMPatrick Munro
Patrick Munro
PMPierre Marty
Pierre Marty
Here we engineered transgenic Leishmania infantum that express luciferase, the objectives being to more easily monitor in real time their establishment either in BALB/c mice—the liver and spleen being mainly studied—or in vitro. Whatever stationary phase L. infantum promastigotes population—wild type or engineered to express luciferase—the parasite burden was similar in the liver and the spleen at day 30 post the intravenous inoculation of BALB/c mice. Imaging of L. infantum hosting BALB/C mice provided sensitivity in the range of 20,000 to 40,000 amastigotes/mg tissue, two tissues—liver and spleen—being monitored. Once sampled and processed ex vivo for their luciferin-dependent bioluminescence the threshold sensitivity was shown to range from 1,000 to 6,000 amastigotes/mg tissue. This model further proved to be valuable for in vivo measurement of the efficiency of drugs such as miltefosine and may, therefore, additionally be used to evaluate vaccine-induced protection. Leishmania infantum/L. chagasi parasites are inoculated in the skin of mammals by sand flies. Though most often these L. infantum-mammal interactions are asymptomatic, they can proceed, in some individuals, to a systemic disease known as visceral leishmaniasis. If left untreated this disease is fatal. The lack of protective or curative vaccines and the limited number of parasite-targeting drugs were incentive to set up experimental conditions that could allow easy monitoring of the fluctuation of the population size of parasites in living laboratory animals. Thus, in the present report, we depict two distinct readout assays that rely on a population of L. infantum we genetically engineered for stably expressing the firefly luciferase gene. These transgenic parasites were either inoculated to BALB/c mice or added to a culture of monocytic cells. Post intravenous inoculation, BALB/c mice were imaged over time, with special attention being given to the liver and the spleen. The sensitivity of this technique ranged from 20,000 to 40,000 parasites/mg of tissue and from 1,000 to 6,000 parasites/mg tissue, for in vivo and ex vivo measurements, respectively. Though preliminary, the data, relying on monocytic cells, are promising for further in vitro screening of small compound libraries.

1 September 2019 in Acta Tropica
Verified
Journal Article
Closed access
ASAurélie Schwing
Aurélie Schwing
CPChristelle Pomares
Christelle Pomares
AMAlissa Majoor
Alissa Majoor
Laurent BoyerLaurent Boyer
Laurent Boyer
PMPierre Marty
Pierre Marty
GMGrégory Michel
Grégory Michel

3 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GMGrégory Michel
Grégory Michel
BFBernard Ferrua
Bernard Ferrua
PMPatrick Munro
Patrick Munro
LBLaurent Boyer
Laurent Boyer
NMNassim Mathal
Nassim Mathal
ELEmmanuel Lemichez
Emmanuel Lemichez
There is a need to develop new effective immunoadjuvants for prophylactic or therapeutic vaccines against intracellular pathogens. The activation of Rho GTPases by bacterial cytotoxic necrotizing factor 1 (CNF1) elicits humoral protective responses against protein antigens. Here, we set out to investigate whether CNF1 activity initiates humoral immunity against co-administered parasite antigens and anti-microbial immune signaling. We report that co-administration of wild-type (WT) CNF1 with Leishmania (L.) promastigote antigens at the nasal mucosa triggered prophylactic and curative vaccine responses against this parasite. Vaccination of the mucosa with promastigote lysate antigens combined with WT CNF1 conferred protection against high inoculum L. infantum infection, which reached 82% in the spleen. Immune parameter analysis by antigen recall indicated robust T-helper (Th)1 polarization of immune memory cells, with high IL-2 and IFN-γ production combined with decreased IL-4 production. Additionally, we explored the curative effect of WT CNF1 on previously infected animals. We observed that PL combined with WT CNF1, but not the inactive C866S mutant CNF1 (mCNF1), induced a 58% decrease in the parasite burden in the spleen.

1 January 2011
Verified
Journal Article
Closed access
PMPierre Marty
Pierre Marty
CPChristelle Pomares
Christelle Pomares
GMGrégory Michel
Grégory Michel
PDPascal Delaunay
Pascal Delaunay
BFBernard Ferrua
Bernard Ferrua
EREric Rosenthal
Eric Rosenthal